AZNCF News and Press, AstraZeneca Plc From 02/21/24

2024-02-21 11:51:31 ET Summary AstraZeneca PLC has announced a deal to acquire Gracell Biotechnologies Inc., a Chinese company focused on developing cell therapies for cancer and autoimmune diseases. The terms of the acquisition include a cash payment of $10 per Gracell ADR and a ...

2024-02-20 17:40:54 ET Summary I have been tracking M&A stocks for almost 30 years and sharing insights with the Seeking Alpha community. The article focuses on M&A funds that own at least 3.5% of a stock involved in a merger or buyout. I highlight several stocks, incl...

2024-02-20 11:05:26 ET More on AstraZeneca PLC AstraZeneca PLC (AZN) Q4 2023 Earnings Call Transcript AstraZeneca PLC 2023 Q4 - Results - Earnings Call Presentation AstraZeneca's Q4 Earnings: Recognizing The Underrated Gem's Growth Daiichi Sankyo-AstraZeneca ...

2024-02-19 07:36:17 ET Read the full article on Seeking Alpha For further details see: Daiichi Sankyo-AstraZeneca gets BLA approved for lung cancer therapy in the U.S.

2024-02-18 02:05:00 ET Summary LianBio plans to stop all its operations by the end of 2024 and will distribute a $4.80 dividend/share ($528M) to its shareholders. Yiviva signed a memorandum of understanding with AstraZeneca China for an R&D collaboration at AstraZeneca’...

2024-02-15 15:00:53 ET Summary Aurinia Pharmaceuticals Inc. stock price dropped 25% after underwhelming Q4 and full-year 2023 results. Sales of Lupkynis, indicated for lupus nephritis and the company's only commercial product, have failed to meet expectations. Aurinia has init...

2024-02-11 06:01:19 ET Summary AstraZeneca has made a tender offer to acquire Icosavax's shares for $15 per share, with a contingent value right worth up to $5. The CVR includes milestone payouts based on FDA approval and net sales of ICVX products in certain regions. The acqu...

2024-02-09 09:33:11 ET Summary Mineralys Therapeutics, Inc. has two ongoing studies evaluating use of lorundrostat for the treatment of patients with uncontrolled or resistant hypertension; these are ADVANCE-HTN and LAUNCH-HTN. Results from the phase 3 ADVANCE-HTN study using loru...

2024-02-09 02:51:35 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

2024-02-08 15:10:05 ET AstraZeneca PLC (AZN) Q4 2023 Earnings Conference Call February 8, 2024, 06:45 AM ET Company Participants Andy Barnett - Head, IR Pascal Soriot - CEO Aradhana Sarin - CFO David Fredrickson - EVP, Oncology Business Susan Galbraith - ...